摘要
目的探讨Ⅲ型前列腺炎患者的治疗。方法门诊收治的186例难治性Ⅲ型前列腺炎患者,随机分为A、B、C3组,A组单用左氧氟沙星治疗,B组选用左氧氟沙星+坦索洛辛治疗,C组选用左氧氟沙星+坦索洛辛+芬必得治疗,疗程4～8周。用NIH-CPSI前列腺炎症状评分作为疗效判断的标准。结果A组与B、C组之间疗效差异具有显著性(P<0.05及P<0.01),B、C组之间疗效无明显差异(P>0.05)。结论α受体阻滞剂在Ⅲ型前列腺炎患者的治疗中有重要的作用。
Objective To investigate the treatment of type Ⅲ prostatitis. Method One hundred and eighty-six out-patient type Ⅲ refractory prostatitis cases were divided into three groups, A,B and C randomly. Levofloxacin alone was used in group A, Levofloxacin and Tamsulosin were used in group B, and Levofloxacin, Tamsulosin and Fenbid were used in group C. The course of treatment was 4-8 weeks. NIH-CPSI was applied to evaluate the therapeutic effect. Results The therapeutic efficacy existed significant differences between group A and both groups B and C (P<0.05 and P<0.01), and similar between group B and C(P>0.05). Conclusion α receptor blocking agents play an important role in treatment of type Ⅲ prostatitis.
出处
《实用预防医学》
CAS
2005年第4期772-773,共2页
Practical Preventive Medicine
